Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay

被引:63
|
作者
Clerico, A
Zucchelli, GC
Pilo, A
Passino, C
Emdin, M
机构
[1] CNR, Inst Clin Physiol, Lab Cardiovasc Endocrinol & Cell Biol, I-56126 Pisa, Italy
[2] Scuola Super Sant Anna, Pisa, Italy
关键词
acute coronary syndrome; atrial natriuretic; peptide (ANP); biological variation; brain natriuretic peptide (BNP); cardiac function; cardiac natriuretic hormones; cardiovascular diseases; heart failure;
D O I
10.1515/CCLM.2006.063
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The clinical relevance of brain natriuretic peptide ( BNP) and N-terminal ( NT)-proBNP assays as a diagnostic tool and prognostic marker in patients with cardiovascular diseases has recently been confirmed. However, several studies demonstrated variation of intra-individual BNP concentrations of >30% ( ranging from 30% to 50%) with reference change values at the 95% confidence interval ( i.e., the estimated critical difference) ranging from 99% to 130% in healthy subjects and heart failure patients. According to this estimated confidence interval, only a great variation in plasma BNP levels should be considered significant in an individual patient ( for example, a decrease of >50% or an increase of more than two-fold). Many recent clinical studies have demonstrated that BNP variations below this estimated critical difference could also have clinical relevance. Like the concentration of other neuro-hormones, levels of plasma BNP fluctuate widely and rapidly along with heart rhythm and blood pressure variations in response to physiological stimuli. However, biological variation of BNP should not be interpreted strictly as random fluctuation around a homeostatic set point, as assumed by the common model used in all studies on biological variation of BNP reported in the literature. These results cannot be directly transferred to clinical practice. While awaiting more accurate studies, we suggest that variations of plasma BNP three-fold greater than the analytical imprecision should be considered as potentially relevant from a physiological and clinical point of view.
引用
收藏
页码:366 / 378
页数:13
相关论文
共 50 条
  • [31] Agreement of BNP and NT-proBNP and the influence of clinical and laboratory variables
    Cardoso Curiati, Milena Novaes
    Silvestre, Odilson Marcos
    Tachotti Pires, Lucas Jose
    Mangini, Sandrigo
    Pires, Philippe Vieira
    Gaiotto, Fabio Antonio
    Laurino, Andre Micheletto
    Pego-Fernandes, Paulo Manuel
    dos Santos Ferreira, Carlos Eduardo
    Bacal, Fernando
    EINSTEIN-SAO PAULO, 2013, 11 (03): : 273 - 277
  • [32] Chapter 9 Natriuretic peptides (BNP and NT-proBNP) and risk of cardiovascular disease
    Christenson, Robert H.
    Myer, Gary L.
    Cooper, Gerald R.
    ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2010, 44 (03): : 454 - 458
  • [33] Performance characteristics of N terminal pro brain natriuretic peptide (NT-ProBNP) and BNP assays in the diagnosis of heart failure in community settings
    Hobbs, FDR
    Davis, RC
    Roalfe, AK
    Trawinski, J
    Davies, MK
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 147A - 147A
  • [34] Direct comparison of transcardiac difference of Brain Natriuretic Peptide (BNP) and N-terminal pro BNP (NT-proBNP) in patients with stable coronary artery disease
    Sakai, H.
    Tsutamoto, T.
    Tanaka, T.
    Horie, M.
    EUROPEAN HEART JOURNAL, 2007, 28 : 568 - 568
  • [35] Reduction of unnecessary N-terminal pro-brain natriuretic peptide (NT-proBNP) tests: A further lesson in demand management
    Livingston, Mark
    Kalansooriya, Anura
    Hartland, Andrew
    Fryer, Anthony A.
    Gupta, Jayant
    Heald, Adrian H.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2018, 72 (04)
  • [36] Relevance of serial measurements of N-terminal-pro-brain natriuretic peptide (NT-PROBNP) in an outpatients ward for heart failure
    Dilek, Cilesiz
    Rudolf, Jarai
    Jaqueline, Cup
    Ilyas, Kozanli
    Gabriele, Jakl
    Kurt, Huber
    CARDIOVASCULAR DRUGS AND THERAPY, 2007, 21 : S32 - S32
  • [37] Relevance of serial measurements of N-Terminal-Pro-Brain Natriuretic Peptide (Nt-proBNP) in an outpatients ward for heart failure
    Jarai, R.
    Cilesiz, D.
    Cup, J.
    Primus, C.
    Kozanli, I.
    Jakl, G.
    Huber, K.
    EUROPEAN HEART JOURNAL, 2007, 28 : 766 - 766
  • [38] Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay
    Yeo, KTJ
    Wu, AHB
    Apple, FS
    Kroll, MH
    Christenson, RH
    Lewandrowski, KB
    Sedor, FA
    Butch, AW
    CLINICA CHIMICA ACTA, 2003, 338 (1-2) : 107 - 115
  • [39] Direct comparison of B-type natriuretic peptide (bnp) and N-terminal ProBNP (NT-proBNP) for the diagnosis of cardiac diseases
    Hiemetzberger, R.
    Falkensammer, G.
    Pachinger, O.
    Griesmacher, A.
    Mair, J.
    WIENER KLINISCHE WOCHENSCHRIFT, 2006, 118 (17-18) : A42 - A42
  • [40] N-terminal pro brain natriuretic peptide (NT-proBNP) concentrations in patients with acromegaly
    Gruson, D
    Alexopoulou, O
    Maiter, D
    Ketelslegers, JM
    CLINICA CHIMICA ACTA, 2005, 355 : S260 - S260